

# Interruption of Antiretroviral Therapy and Risk of Cardiovascular Disease in HIV-1 Infection: Exploratory Analyses from the SMART Study

Antiviral Therapy

13, 177-188

DOI: [10.1177/135965350801300215](https://doi.org/10.1177/135965350801300215)

Citation Report

#	ARTICLE	IF	CITATIONS
3	Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. <i>Lancet</i> , The, 2008, 371, 1417-1426.	6.3	809
5	The role of HIV in serious diseases other than AIDS. <i>Aids</i> , 2008, 22, 2409-2418.	1.0	227
6	Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. <i>Aids</i> , 2008, 22, F17-F24.	1.0	300
8	Cardiovascular Risk Assessment in Antiretroviral-Naïve HIV Patients. <i>AIDS Patient Care and STDs</i> , 2009, 23, 809-813.	1.1	29
9	Continuous antiretroviral therapy decreases bone mineral density. <i>Aids</i> , 2009, 23, 1519-1529.	1.0	188
10	Cardiovascular risk factors and ultrasound evaluation of carotid atherosclerosis in patients with HIV-1 infection. <i>International Journal of STD and AIDS</i> , 2009, 20, 683-689.	0.5	14
11	Metabolic and cardiovascular complications of HIV. <i>Medicine</i> , 2009, 37, 348-351.	0.2	1
12	HIV infection and abnormal regional ventricular function. <i>International Journal of Cardiovascular Imaging</i> , 2009, 25, 809-817.	0.7	15
14	HIV-associated vascular diseases: Structural and functional changes, clinical implications. <i>International Journal of Cardiology</i> , 2009, 133, 293-306.	0.8	64
15	Lipoprotein particle subclasses, cardiovascular disease and HIV infection. <i>Atherosclerosis</i> , 2009, 207, 524-529.	0.4	100
17	Cardiovascular disease and HIV infection: host, virus, or drugs?. <i>Current Opinion in Infectious Diseases</i> , 2009, 22, 28-34.	1.3	47
18	Planning for Posttrial Access to Antiretroviral Treatment for Research Participants in Developing Countries. <i>American Journal of Public Health</i> , 2009, 99, 1556-1562.	1.5	20
19	The effects of intermittent, CD4-guided antiretroviral therapy on body composition and metabolic parameters. <i>Aids</i> , 2010, 24, 353-563.	1.0	13
20	From lipodystrophy to cardiovascular disease: new insight into the management of HIV infection. <i>Clinical Lipidology</i> , 2010, 5, 583-593.	0.4	0
21	Soluble biomarkers and morbidity and mortality among people infected with HIV: summary of published reports from 1997 to 2010. <i>Current Opinion in HIV and AIDS</i> , 2010, 5, 480-490.	1.5	33
22	Effect of Nevirapine on the Steady-State Trough Concentrations of Atazanavir in HIV-Infected Patients Receiving Atazanavir/Ritonavir. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 93-96.	1.0	6
23	Postprandial lipid effects of low-dose ritonavir vs. raltegravir in HIV-uninfected adults. <i>Aids</i> , 2010, 24, 1727-1731.	1.0	17
24	Effect of Highly Active Antiretroviral Therapy on Homocysteine Plasma Concentrations in HIV-1-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 54, 477-481.	0.9	7

#	ARTICLE	IF	CITATIONS
25	Premature onset of cardiovascular disease in HIV-infected individuals: the drugs and the virus. <i>HIV Therapy</i> , 2010, 4, 675-692.	0.6	4
26	CD4 <sup>+</sup> T-cell-guided structured treatment interruptions of antiretroviral therapy in HIV disease: Projecting beyond clinical trials. <i>Antiviral Therapy</i> , 2010, 15, 351-361.	0.6	8
27	Risk of Myocardial Infarction in Patients with HIV Infection Exposed to Specific Individual Antiretroviral Drugs from the 3 Major Drug Classes: The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. <i>Journal of Infectious Diseases</i> , 2010, 201, 318-330.	1.9	575
28	High-Density Lipoprotein Particles and Markers of Inflammation and Thrombotic Activity in Patients with Untreated HIV Infection. <i>Journal of Infectious Diseases</i> , 2010, 201, 285-292.	1.9	89
29	Risk of cardiovascular disease in HIV-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 386-389.	1.3	16
30	Short Communication: Contribution of the Immunovirological State and Traditional Cardiovascular Risk Factors to Low HDL-Cholesterol in HIV Patients. <i>AIDS Research and Human Retroviruses</i> , 2010, 26, 1167-1170.	0.5	3
31	The macrophage: the intersection between HIV infection and atherosclerosis. <i>Journal of Leukocyte Biology</i> , 2009, 87, 589-598.	1.5	119
32	Association of Immunologic and Virologic Factors With Myocardial Infarction Rates in a US Healthcare System. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 55, 615-619.	0.9	148
33	Traditional risk factors and D-dimer predict incident cardiovascular disease events in chronic HIV infection. <i>Aids</i> , 2010, 24, 1509-1517.	1.0	173
34	Changes in Lipids and Lipoprotein Particle Concentrations After Interruption of Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 54, 275-284.	0.9	14
35	Serious Fatal and Nonfatal Non-AIDS-Defining Illnesses in Europe. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 55, 262-270.	0.9	243
36	Switching antiretroviral therapy to minimize metabolic complications. <i>HIV Therapy</i> , 2010, 4, 693-711.	0.6	9
37	Enfermedad cardiovascular en el paciente infectado por el virus de la inmunodeficiencia humana. <i>Hipertension Y Riesgo Vascular</i> , 2010, 27, 162-170.	0.3	1
39	Heightened inflammation is linked to carotid intima-media thickness and endothelial activation in HIV-infected children. <i>Atherosclerosis</i> , 2010, 211, 492-498.	0.4	63
40	Posterior reversible encephalopathy syndrome in una paziente con AIDS, insufficienza renale acuta, ipertensione arteriosa. <i>Italian Journal of Medicine</i> , 2011, 5, 190-193.	0.2	0
41	HIV treatment for prevention. <i>Journal of the International AIDS Society</i> , 2011, 14, 28-28.	1.2	30
42	Cardiovascular Disease and Therapeutic Drug-Related Cardiovascular Consequences in HIV-Infected Patients. <i>American Journal of Cardiovascular Drugs</i> , 2011, 11, 383-394.	1.0	31
44	The metabolic syndrome in HIV. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2011, 25, 479-486.	2.2	26

#	ARTICLE	IF	CITATIONS
45	Noninvasive Coronary Imaging for Atherosclerosis in Human Immunodeficiency Virus Infection. <i>Current Problems in Diagnostic Radiology</i> , 2011, 40, 262-267.	0.6	4
46	Cardiovascular implications of HIV-induced dyslipidemia. <i>Atherosclerosis</i> , 2011, 219, 384-389.	0.4	58
47	Cardiovascular Disease Risk in Pediatric HIV: The Need for Population-Specific Guidelines. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 57, 351-354.	0.9	3
48	Systemic Immune Activation in HIV Infection Is Associated with Decreased MDC Responsiveness to TLR Ligand and Inability to Activate Naive CD4 T-Cells. <i>PLoS ONE</i> , 2011, 6, e23884.	1.1	23
49	Elevated triglycerides and risk of myocardial infarction in HIV-positive persons. <i>Aids</i> , 2011, 25, 1497-1504.	1.0	39
50	Secondary complications and co-infections in the HIV-infected adolescent in the antiretroviral era. <i>Current Opinion in Infectious Diseases</i> , 2011, 24, 212-218.	1.3	1
51	Clinical implications of fixed-dose coformulations of antiretrovirals on the outcome of HIV-1 therapy. <i>Aids</i> , 2011, 25, 1683-1690.	1.0	43
52	Cardiovascular disease in HIV infection. <i>Current Opinion in HIV and AIDS</i> , 2011, 6, 266-271.	1.5	87
53	N-terminal-proB-type natriuretic peptide predicts cardiovascular disease events in HIV-infected patients. <i>Aids</i> , 2011, 25, 651-657.	1.0	29
54	Assessment and modification of cardiovascular disease risk in the HIV-infected individual. <i>Future Virology</i> , 2011, 6, 307-320.	0.9	2
55	Haemoglobin and Anaemia in the Smart Study. <i>Antiviral Therapy</i> , 2011, 16, 329-337.	0.6	12
56	Cardiovascular Complications in Children with HIV Infection. <i>Current HIV/AIDS Reports</i> , 2011, 8, 209-214.	1.1	15
57	When to Start Antiretroviral Therapy. <i>Current Infectious Disease Reports</i> , 2011, 13, 60-67.	1.3	3
58	Management of dyslipidemia in HIV-infected patients. <i>Clinical Lipidology</i> , 2011, 6, 447-462.	0.4	28
59	Association of Age and Comorbidity with Physical Function in HIV-Infected and Uninfected Patients: Results from the Veterans Aging Cohort Study. <i>AIDS Patient Care and STDs</i> , 2011, 25, 13-20.	1.1	105
60	Plasma Levels of Soluble CD14 Independently Predict Mortality in HIV Infection. <i>Journal of Infectious Diseases</i> , 2011, 203, 780-790.	1.9	957
61	HIV infection, aging and cardiovascular disease: epidemiology and prevention. <i>Sexual Health</i> , 2011, 8, 465.	0.4	24
62	Keeping Them in "Finding, Linking, and Retaining Young HIV-Positive Black and Latino Men Who Have Sex with Men in Care. <i>AIDS Patient Care and STDs</i> , 2011, 25, 37-45.	1.1	76

#	ARTICLE	IF	CITATIONS
63	Trends Related to Aging and Co-Occurring Disorders in HIV-Infected Drug Users. <i>Substance Use and Misuse</i> , 2011, 46, 233-244.	0.7	10
64	Immune Dysregulation and Vascular Risk in HIV-Infected Patients: Implications for Clinical Care. <i>Journal of Infectious Diseases</i> , 2011, 203, 439-441.	1.9	12
65	Abacavir Use and Risk of Acute Myocardial Infarction and Cerebrovascular Events in the Highly Active Antiretroviral Therapy Era. <i>Clinical Infectious Diseases</i> , 2011, 53, 84-91.	2.9	145
66	Longitudinal assessment of cardiac diastolic function in HIV-infected patients. <i>International Journal of STD and AIDS</i> , 2012, 23, 105-110.	0.5	20
67	HIV Replication and Immune Status Are Independent Predictors of the Risk of Myocardial Infarction in HIV-Infected Individuals. <i>Clinical Infectious Diseases</i> , 2012, 55, 600-607.	2.9	141
68	Nutrition and the HIV-associated lipodystrophy syndrome. <i>Nutrition Research Reviews</i> , 2012, 25, 267-287.	2.1	31
69	Dyslipidaemia in HIV-1-infected patients receiving protease inhibitors after initial treatment with first-line-based non-nucleoside reverse transcriptase inhibitors: a cross-sectional study. <i>BMJ Open</i> , 2012, 2, e001317.	0.8	5
70	Cystatin C in HIV-infected patients: promising but not yet ready for prime time. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 1305-1313.	0.4	31
71	Effect of Darunavir on Lipid Profile in HIV-Infected Patients. <i>HIV Clinical Trials</i> , 2012, 13, 256-270.	2.0	29
72	Asymmetric Dimethylarginine Concentrations Decrease in Patients with HIV Infection under Antiretroviral Therapy. <i>Antiviral Therapy</i> , 2012, 17, 1021-1027.	0.6	12
73	Antiviral agents and HIV prevention. <i>Aids</i> , 2012, 26, 1585-1598.	1.0	89
74	Novel clinical trial designs for the development of new antiretroviral agents. <i>Aids</i> , 2012, 26, 899-907.	1.0	13
75	Impact of highly active antiretroviral therapy on the molecular epidemiology of newly diagnosed HIV infections. <i>Aids</i> , 2012, 26, 2079-2086.	1.0	47
76	Short-Term and Long-Term Clinical and Immunological Consequences of Stopping Antiretroviral Therapy in HIV-Infected Patients with Preserved Immune Function. <i>Antiviral Therapy</i> , 2013, 18, 125-130.	0.6	17
77	The Clinical Benefits of Antiretroviral Therapy in Severely Immunocompromised HIV-1-Infected Patients with and without Complete Viral Suppression. <i>Antiviral Therapy</i> , 2012, 17, 1291-1300.	0.6	10
78	Episodes of HIV Viremia and the Risk of Non-AIDS Diseases in Patients on Suppressive Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 60, 265-272.	0.9	28
79	Case 30-2012. <i>New England Journal of Medicine</i> , 2012, 367, 1246-1254.	13.9	2
80	Elevated D-Dimer is Independently Associated with Endothelial Dysfunction: A Cross-Sectional Study in HIV-Infected Adults on Antiretroviral Therapy. <i>Antiviral Therapy</i> , 2012, 17, 1345-1349.	0.6	32

#	ARTICLE	IF	CITATIONS
81	18FDG PET-CT imaging detects arterial inflammation and early atherosclerosis in HIV-infected adults with cardiovascular disease risk factors. <i>Journal of Inflammation</i> , 2012, 9, 26.	1.5	44
82	The feature of Metabolic Syndrome in HIV naive patients is not the same of those treated: Results from a prospective study. <i>Biomedicine and Pharmacotherapy</i> , 2012, 66, 348-353.	2.5	20
83	Soluble mediators of inflammation in HIV and their implications for therapeutics and vaccine development. <i>Cytokine and Growth Factor Reviews</i> , 2012, 23, 193-206.	3.2	44
85	Efficacy and safety of switching suppressed patients with elevated triglycerides from lopinavir/ritonavir or fosamprenavir/ritonavir to atazanavir/ritonavir or darunavir/ritonavir based therapy: The LARD study. <i>HIV and AIDS Review</i> , 2012, 11, 77-83.	0.1	2
86	Microbial translocation in HIV infection: causes, consequences and treatment opportunities. <i>Nature Reviews Microbiology</i> , 2012, 10, 655-666.	13.6	373
87	Inflammation, Coagulation and Cardiovascular Disease in HIV-Infected Individuals. <i>PLoS ONE</i> , 2012, 7, e44454.	1.1	456
88	Antiretroviral Treatment of Adult HIV Infection. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 387-402.	3.8	1,239
89	Accelerated aging and human immunodeficiency virus infection: Emerging challenges of growing older in the era of successful antiretroviral therapy. <i>Journal of NeuroVirology</i> , 2012, 18, 247-255.	1.0	64
90	Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis. <i>HIV Medicine</i> , 2012, 13, 453-468.	1.0	346
91	Impact of antiretroviral therapy interruption on plasma biomarkers of cardiovascular risk and lipids: 144-week final data from the STOPAR study. <i>HIV Medicine</i> , 2012, 13, 488-498.	1.0	9
92	Relationship between total bilirubin and endothelial function, inflammation and oxidative stress in HIV-infected adults on stable antiretroviral therapy. <i>HIV Medicine</i> , 2012, 13, 609-616.	1.0	19
93	British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. <i>HIV Medicine</i> , 2012, 13, 1-6.	1.0	149
94	8.0 Antiretroviral therapy in specific populations. <i>HIV Medicine</i> , 2012, 13, 57-81.	1.0	1
95	Considerations for Endpoint Selection When Designing HIV Clinical Trials. <i>Current Infectious Disease Reports</i> , 2012, 14, 110-118.	1.3	1
96	Insulin resistance, lipodystrophy and cardiometabolic syndrome in HIV/AIDS. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2013, 14, 133-140.	2.6	43
97	Antiretroviral Therapy for Prevention Is a Combination Strategy. <i>Current HIV/AIDS Reports</i> , 2013, 10, 152-158.	1.1	32
98	Dyslipidemia, atherosclerosis and cardiovascular disease: an increasingly important triad in an aging population living with HIV. <i>Future Virology</i> , 2013, 8, 1021-1034.	0.9	8
99	Metabolic Syndrome in Human Immunodeficiency Virus-Positive Subjects: Prevalence, Phenotype, and Related Alterations in Arterial Structure and Function. <i>Metabolic Syndrome and Related Disorders</i> , 2013, 11, 403-411.	0.5	30

#	ARTICLE	IF	CITATIONS
100	The effect of HIV infection on atherosclerosis and lipoprotein metabolism: A one year prospective study. <i>Atherosclerosis</i> , 2013, 229, 206-211.	0.4	31
101	Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study. <i>Clinical Trials</i> , 2013, 10, S5-S36.	0.7	100
102	Associations between immune depression and cardiovascular events in HIV infection. <i>Aids</i> , 2013, 27, 2735-2748.	1.0	51
103	HIV and cardiovascular disease: comment on Islam <i>et al</i> .. <i>HIV Medicine</i> , 2013, 14, 517-518.	1.0	2
104	Cardiovascular risk among HIV-positive subjects preceding exposure to HAART: a retrospective claims analysis. <i>Future Virology</i> , 2013, 8, 849-860.	0.9	1
105	Ultrasonographic measures of cardiovascular disease risk in antiretroviral treatment-naive individuals with HIV infection. <i>Aids</i> , 2013, 27, 929-937.	1.0	43
106	Cardiovascular Disease Risk Factors in HIV-Infected Women After Initiation of Lopinavir/Ritonavir- and Nevirapine-Based Antiretroviral Therapy in Sub-Saharan Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 66, 155-163.	0.9	16
107	Cytomegalovirus proctitis mimicking rectal cancer in an immunocompetent elderly patient: a case report. <i>BMC Research Notes</i> , 2014, 7, 799.	0.6	6
108	Immunodeficiency and Risk of Myocardial Infarction Among HIV-Positive Individuals With Access to Care. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 65, 160-166.	0.9	143
110	MECHANISMS IN ENDOCRINOLOGY: Metabolic and body composition effects of newer antiretrovirals in HIV-infected patients. <i>European Journal of Endocrinology</i> , 2014, 170, R185-R202.	1.9	67
111	Initiation of antiretroviral therapy at high CD4 cell counts. <i>Current Opinion in HIV and AIDS</i> , 2014, 9, 54-62.	1.5	28
112	Cardiovascular disease in human immunodeficiency virus. <i>Internal Medicine Journal</i> , 2014, 44, 315-324.	0.5	13
113	Effect of AIDS on Women Who Have Sex-Determined Health Issues. <i>Seminars in Nuclear Medicine</i> , 2014, 44, 489-498.	2.5	3
114	Risk of coronary heart disease in patients with HIV infection. <i>Nature Reviews Cardiology</i> , 2014, 11, 728-741.	6.1	90
115	Determinants of developing widened spatial QRS-T angle in HIV-infected individuals: Results from the Strategies for Management of Antiretroviral Therapy [SMART] Study. <i>Journal of Electrocardiology</i> , 2014, 47, 264-271.	0.4	3
116	Cardiovascular biomarkers in vertically HIV-infected children without metabolic abnormalities. <i>Atherosclerosis</i> , 2014, 233, 410-414.	0.4	20
117	The aging HIV population. <i>Clinical Practice (London, England)</i> , 2014, 11, 221-231.	0.1	3
118	Coronary Artery Disease in Patients with HIV Infection. <i>American Journal of Cardiovascular Drugs</i> , 2015, 15, 81-87.	1.0	15

#	ARTICLE	IF	CITATIONS
119	Future challenges for clinical care of an ageing population infected with HIV: a modelling study. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 810-818.	4.6	634
120	Time trends for risk of severe age-related diseases in individuals with and without HIV infection in Denmark: a nationwide population-based cohort study. <i>Lancet HIV</i> , the, 2015, 2, e288-e298.	2.1	173
121	Antiretroviral Therapy in the Elite Controller: Justified or Premature?. <i>Journal of Infectious Diseases</i> , 2015, 211, 1689-1691.	1.9	5
122	Brachial and central blood pressure in HIV-infected subjects. <i>Hypertension Research</i> , 2015, 38, 405-412.	1.5	13
123	Community perspective on the <scp>INSIGHT S</scp>trategic <scp>T</scp>iming of <scp>AntiRetroviral T</scp>reatment (<scp>START</scp>) trial. <i>HIV Medicine</i> , 2015, 16, 10-13.	1.0	12
125	Use of a Real-Time Alert System to Identify and Re-Engage Lost-to-Care HIV Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 72, e52-e55.	0.9	8
126	Effects of Antiretroviral Therapy on Immune Function and Arterial Inflammation in Treatment-Naive Patients With Human Immunodeficiency Virus Infection. <i>JAMA Cardiology</i> , 2016, 1, 474.	3.0	66
127	A cross-sectional study to evaluate the association of hyperbilirubinaemia on markers of cardiovascular disease, neurocognitive function, bone mineral density and renal markers in HIV-1 infected subjects on protease inhibitors. <i>HIV Clinical Trials</i> , 2016, 17, 123-130.	2.0	6
128	Hypertension Is a Key Feature of the Metabolic Syndrome in Subjects Aging with HIV. <i>Current Hypertension Reports</i> , 2016, 18, 46.	1.5	36
129	Atazanavir and Cardiovascular Risk Among Human Immunodeficiency Virus-Infected Patients: A Systematic Review. <i>Infectious Diseases and Therapy</i> , 2016, 5, 473-489.	1.8	14
130	British HIV Association guidelines for the treatment of <scp>HIV</scp>â€”positive adults with antiretroviral therapy 2015. <i>HIV Medicine</i> , 2016, 17, s2-s104.	1.0	78
131	Baseline, Time-Updated, and Cumulative HIV Care Metrics for Predicting Acute Myocardial Infarction and All-Cause Mortality. <i>Clinical Infectious Diseases</i> , 2016, 63, 1423-1430.	2.9	36
132	Contribution of antiretroviral therapy to cardiovascular disease risk in HIV-infected patients. <i>Future Virology</i> , 2016, 11, 509-527.	0.9	2
133	Traditional and HIV-specific risk factors for cardiovascular morbidity and mortality among HIV-infected adults in Brazil: a retrospective cohort study. <i>BMC Infectious Diseases</i> , 2016, 16, 376.	1.3	19
134	Unstructured treatment interruption. <i>Aids</i> , 2016, 30, 2373-2378.	1.0	7
135	Interference with purinergic signalling. <i>Aids</i> , 2016, 30, 1341-1351.	1.0	10
136	HIV and its relationship to insulin resistance and lipid abnormalities. <i>Translational Research</i> , 2017, 183, 41-56.	2.2	37
137	Projecting 10-year, 20-year, and Lifetime Risks of Cardiovascular Disease in Persons Living With Human Immunodeficiency Virus in the United States. <i>Clinical Infectious Diseases</i> , 2017, 65, 1266-1271.	2.9	48



#	ARTICLE	IF	CITATIONS
138	Acute coronary syndromes in patients with HIV. <i>Coronary Artery Disease</i> , 2017, 28, 166-172.	0.3	25
139	Cardiovascular outcomes among HIV-infected veterans receiving atazanavir. <i>Aids</i> , 2017, 31, 2095-2106.	1.0	25
140	Issues in the Aging HIV-Positive Patient. , 2017, , 927-930.e1.		0
141	Metabolic disorders and cardiovascular risk in people living with HIV/AIDS without the use of antiretroviral therapy. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2017, 50, 598-606.	0.4	19
142	The association between HIV and atherosclerotic cardiovascular disease in sub-Saharan Africa: a systematic review. <i>BMC Public Health</i> , 2017, 17, 954.	1.2	43
143	Cardiovascular Risk Prediction Functions Underestimate Risk in HIV Infection. <i>Circulation</i> , 2018, 137, 2203-2214.	1.6	151
144	Metabolic and Cardiac Adaptation to Chronic Pharmacologic Blockade of Facilitative Glucose Transport in Murine Dilated Cardiomyopathy and Myocardial Ischemia. <i>Scientific Reports</i> , 2018, 8, 6475.	1.6	8
145	HIV infection and lipids. <i>Current Opinion in Cardiology</i> , 2018, 33, 429-435.	0.8	7
146	Contemporary protease inhibitors and cardiovascular risk. <i>Current Opinion in Infectious Diseases</i> , 2018, 31, 8-13.	1.3	28
147	Hypertension in HIV-Infected Adults. <i>Hypertension</i> , 2018, 72, 44-55.	1.3	123
148	HIV infection and stroke. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 152, 187-200.	1.0	16
149	Atherosclerosis in subjects newly diagnosed with human immunodeficiency virus infection. <i>Bioscience Reports</i> , 2018, 38, .	1.1	6
150	Evaluation of inflammatory biomarkers, carotid intima-media thickness and cardiovascular risk in HIV-1 treatment-naïve patients. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2018, 51, 277-283.	0.4	4
151	Incidence and Risk Factors for Overweight and Obesity after Initiation of Antiretroviral Therapy in Dar es Salaam, Tanzania. <i>Journal of the International Association of Providers of AIDS Care</i> , 2018, 17, 232595821875975.	0.6	9
152	Antiretroviral resistance among HIV-1 patients on first-line therapy attending a comprehensive care clinic in Kenyatta National Hospital, Kenya: a retrospective analysis. <i>Pan African Medical Journal</i> , 2018, 29, 186.	0.3	5
153	Cardiovascular disease burden among human immunodeficiency virus-infected individuals. <i>International Journal of Cardiology</i> , 2018, 265, 195-203.	0.8	23
154	The Risk for Sudden Cardiac Death Among Patients Living With Heart Failure and Human Immunodeficiency Virus. <i>JACC: Heart Failure</i> , 2019, 7, 759-767.	1.9	25
155	Heart failure and adverse heart failure outcomes among persons living with HIV in a US tertiary medical center. <i>American Heart Journal</i> , 2019, 210, 39-48.	1.2	23

#	ARTICLE	IF	CITATIONS
156	Vascular Aging and Disease of the Large Vessels: Role of Inflammation. High Blood Pressure and Cardiovascular Prevention, 2019, 26, 175-182.	1.0	51
157	HIV disease, metabolic dysfunction and atherosclerosis: A three year prospective study. PLoS ONE, 2019, 14, e0215620.	1.1	20
158	Comparative Assessment of the Magnitude of Hyperlipidemia in HIV-Infected Patients Receiving Lopinavir/r- and Atazanavir/r-Based Antiretroviral Drugs. Journal of the International Association of Providers of AIDS Care, 2019, 18, 232595821984190.	0.6	6
159	Severe infection increases cardiovascular risk among HIV-infected individuals. BMC Infectious Diseases, 2019, 19, 319.	1.3	13
160	Vascular endothelial dysfunction in the wake of HIV and ART. FEBS Journal, 2019, 286, 1256-1270.	2.2	60
161	Coronary Artery Disease Manifestations in HIV: What, How, and Why. Canadian Journal of Cardiology, 2019, 35, 270-279.	0.8	26
162	Amino-terminal Pro-B-Type Natriuretic Peptide Among Patients Living With Both Human Immunodeficiency Virus and Heart Failure. Clinical Infectious Diseases, 2020, 71, 1306-1315.	2.9	2
163	A comparison between different anti-retroviral therapy regimes on soluble inflammation markers: a pilot study. AIDS Research and Therapy, 2020, 17, 61.	0.7	2
164	Physical activity and exercise to improve cardiovascular health for adults living with HIV. Progress in Cardiovascular Diseases, 2020, 63, 178-183.	1.6	38
165	Early scale-up of antiretroviral therapy at diagnosis for reducing economic burden of cardiometabolic disease in HIV-infected population. Aids, 2020, 34, 903-911.	1.0	2
166	Statins for atherosclerotic cardiovascular disease prevention in people living with HIV in Thailand: a cost-effectiveness analysis. Journal of the International AIDS Society, 2020, 23, e25494.	1.2	5
167	Prediction of future cardiovascular events by Framingham, SCORE and asCVD risk scores is less accurate in HIV-positive individuals from the HIV-HEART Study compared with the general population. HIV Medicine, 2021, 22, 732-741.	1.0	7
168	Analysis of the Coagulation Profile in Children with HIV Infection—Effect of Disease and Anti Retroviral Therapy. Indian Journal of Hematology and Blood Transfusion, 2022, 38, 132-137.	0.3	0
169	Role of Brain Arterial Remodeling in HIV-Associated Cerebrovascular Outcomes. Frontiers in Neurology, 2021, 12, 593605.	1.1	3
170	Managing cardiovascular risk in people living with HIV in Asia—where are we now?. HIV Medicine, 2022, 23, 111-120.	1.0	2
171	HIV Care Among Elderly Population: Systematic Review and Meta-Analysis. AIDS Research and Human Retroviruses, 2020, 36, 475-489.	0.5	19
172	Acute coronary syndrome in human immunodeficiency virus patients: exploiting physiopathology to inform the clinical practice. OA Evidence-Based Medicine, 2013, 1, .	0.1	1
173	Care of the aging HIV patient. Cleveland Clinic Journal of Medicine, 2015, 82, 445-455.	0.6	8

#	ARTICLE	IF	CITATIONS
174	Acute coronary syndrome in HIV patients: from pathophysiology to clinical practice. <i>Cardiovascular Diagnosis and Therapy</i> , 2012, 2, 50-5.	0.7	11
175	GuÃa ClÃnica de VIH/SIDA. <i>Revista Chilena De Infectologia</i> , 2010, 27, .	0.0	2
176	Hyper-inflammation and Endothelial Activation in HIV Infected Patients with Detectable and Undetectable Viral Load. <i>Journal of AIDS &amp; Clinical Research</i> , 2012, 03, .	0.5	2
177	Cardiovascular disease in human immunodeficiency virus infected patients: A true or perceived risk?. <i>World Journal of Cardiology</i> , 2015, 7, 633.	0.5	39
178	Elevated plasma von Willebrand factor levels are associated with subsequent ischemic stroke in persons with treated HIV infection. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab521.	0.4	5
180	Adiponectin Levels and Coronary Artery Disease among HIV-Infected Men. <i>Journal of AIDS &amp; Clinical Research</i> , 2013, 04, .	0.5	0
181	Impact of Antiretroviral Therapy on Selected Metabolic Disorders â€“ Pilot Study. <i>Advances in Clinical and Experimental Medicine</i> , 2014, 23, 539-549.	0.6	1
182	The role of HIV-infection in the development risk factors of cardiovascular diseases in naive HIV-infected patients and HIV-infected patients on antiretroviral therapy. <i>Cardiosomatics</i> , 2014, 5, 36-40.	0.2	4
183	Comparison of Three Cardiovascular Risk Scores among HIV-Infected Patients in Korea: The Korea HIV/AIDS Cohort Study. <i>Infection and Chemotherapy</i> , 2022, 54, 409.	1.0	1
184	Cardiovascular disease risk in women living with HIV. <i>Current Opinion in HIV and AIDS</i> , 2022, 17, 270-278.	1.5	7
185	Association of Cumulative Viral Load With the Incidence of Hypertension and Diabetes in People With HIV. <i>Hypertension</i> , 2022, 79, .	1.3	5
186	Plasma Interleukin-6 (IL-6), Angiotensin-2, and C-Reactive Protein Levels Predict Subsequent Type 1 Myocardial Infarction in Persons With Treated HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2023, 93, 282-291.	0.9	1
187	Intersectionality-informed analysis of durable viral suppression disparities in people with HIV. <i>Aids</i> , 0, Publish Ahead of Print, .	1.0	0